|
|
Article: What's in the pipeline: a look at antipsychotic agents in development.(ANTIPSYCHOTICS)
- Article from:
- Behavioral Healthcare
- Article date:
- December 1, 2007
- Author:
CopyrightCOPYRIGHT 2007 Vendome Group LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The most compelling finding from the recent National Institute of Mental Health-sponsored Clinical Antipsychotic Trials of Intervention Effectiveness or "CATIE" study was that only one in four subjects stayed on their medication. This randomized study compared the effectiveness of several second-generation antipsychotics (SGAs) to one of the first-generation antipsychotics (FGAs). The subjects could have remained on the medication that they received for up to 18 months. Instead 74% switched their antipsychotic either because they or their doctor felt that it wasn't working or side effects were intolerable.
If nothing else, this ambitious project told us that ...